Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J. Hsieh, Robert J. Motzer, Helen Won et al.|European Urology|2016Cited by 204
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M. Syeda, David Polsky, Jennifer Wiggins et al.|The Lancet Oncology|2021Cited by 96
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blastsGuillermo Garcia‐Manero, Oliver G. Ottmann, Mikkael A. Sekeres et al.|Leukemia|2017Cited by 70
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 TrialMartin H. Voss, Robert J. Motzer, Albert Reising et al.|Clinical Cancer Research|2018Cited by 38
Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in <i>PBRM1</i> and <i>BAP1</i> with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.Martin H. Voss, A. Ari Hakimi, Fengshen Kuo et al.|Journal of Clinical Oncology|2017Cited by 28